<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="pathogens-08-00176-t002" orientation="portrait" position="float">
 <object-id pub-id-type="pii">pathogens-08-00176-t002_Table 2</object-id>
 <label>Table 2</label>
 <caption>
  <p>Regimens based on DAAs currently available for treatment of HCV in CKD.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <tbody>
   <tr>
    <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Daclatasvir (60 mg)</td>
    <td rowspan="8" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">CKD stage 1,2,3 </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Elbasvir/Grazoprevir (50 mg/100 mg)</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glecaprevir/Pibrentasvir (300 mg/120 mg)</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ledipasvir/Sofosbuvir (90 mg/400 mg)</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sofosbuvir/Velpatasvir (400 mg/100 mg)</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Simeprevir (150 mg)</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sofosbuvir (400 mg)</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sofosbuvir/Velpatasvir/Voxilaprevir (400 mg/100 mg/100 mg)</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ritonavir-boosted Paritaprevir/Ombitasvir/DasabuvirÂ±Ribavirin
     <break/>(PrOD or 3D regimen) (50 mg/75 mg/12.5 mg/250 mg/200 mg)
    </td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CKD stage 4,5 </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Elbasvir/Grazoprevir (50 mg/100 mg)</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glecaprevir/Pibrentasvir (300 mg/120 mg)</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
